Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017

  • ID: 4457597
  • Report
  • Region: Global
  • 129 pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • Abion Inc
  • AVEO Pharmaceuticals Inc
  • Cytori Therapeutics Inc
  • GlaxoSmithKline Plc
  • LondonPharma Ltd
  • PDS Biotechnology Corp
  • MORE

Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017

Summary

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). There are a total of 163 products in development for this indication, by 118 companies and 25 academic institutions. Key companies operating in this pipeline space include Advaxis, F. Hoffmann-La Roche, GlaxoSmithKline, Kite Pharma, MedImmune and Pfizer.

The most prominent targets in the cervical cancer pipeline are HPV proteins there are a number of products in the pipeline targeting HPV protein E7 and HPV protein E6. Other common targets in the pipeline include vascular endothelial growth factor A and programmed cell death protein 1.

Vaginal cancer is a rare cancer that causes symptoms such as watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. There are a total of 6 products in development for this indication, by 6 companies. The companies operating in this pipeline space are ISA Pharmaceuticals, MedImmune, Ology Bioservices, Ono Pharmaceutical, Oryx GmbH & Co KG and Taiwan Liposome Company.

Finally, Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. There are a total of 5 products in development for this indication, by 5 companies. The five companies operating in this pipeline are Cutanea Life Sciences, ISA Pharmaceuticals, MedImmune, Ono Pharmaceutical and Oryx GmbH & Co KG

The report "Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017" provides an overview of the Lower Female Reproductive System Cancers pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Cervical Cancer, Vaginal Cancer and Vulvar Cancer, and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for genetic ophthalmological disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of genetic ophthalmological disorders?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abion Inc
  • AVEO Pharmaceuticals Inc
  • Cytori Therapeutics Inc
  • GlaxoSmithKline Plc
  • LondonPharma Ltd
  • PDS Biotechnology Corp
  • MORE

1 Table of Contents

2 Introduction
2.1 Lower Female Reproductive System Cancers Report Coverage
2.2 Cervical Cancer - Overview
2.3 Vaginal Cancer - Overview
2.4 Vulvar Cancer - Overview

3 Therapeutics Development
3.1 Cervical Cancer
3.2 Vaginal Cancer
3.3 Vulvar Cancer

4 Therapeutics Assessment
4.1 Cervical Cancer
4.2 Vaginal Cancer
4.3 Vulvar Cancer

5 Companies Involved in Therapeutics Development
5.1 Cervical Cancer
5.2 Vaginal Cancer
5.3 Vulvar Cancer

6 Dormant Projects
6.1 Cervical Cancer
6.2 Vaginal Cancer
6.3 Vulvar Cancer

7 Discontinued Products
7.1 Cervical Cancer

8 Product Development Milestones
8.1 Cervical Cancer
8.2 Vulvar Cancer

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation

List of Tables
Table 1: Number of Products under Development for Cervical Cancer
Table 2: Number of Products under Development by Companies, Cervical Cancer
Table 3: Number of Products under Development by Universities/Institutes, Cervical Cancer
Table 4: Products under Development by Companies, Cervical Cancer
Table 5: Products under Development by Universities/Institutes, Cervical Cancer
Table 6: Number of Products under Development for Vaginal Cancer
Table 7: Number of Products under Development by Companies, Vaginal Cancer
Table 8: Products under Development by Companies, Vaginal Cancer
Table 9: Number of Products under Development for Vulvar Cancer
Table 10: Number of Products under Development by Companies, Vulvar Cancer
Table 11: Products under Development by Companies, Vulvar Cancer
Table 12: Number of Products by Stage and Target, Cervical Cancer
Table 13: Number of Products by Stage and Mechanism of Action, Cervical Cancer
Table 14: Number of Products by Stage and Route of Administration, Cervical Cancer
Table 15: Number of Products by Stage and Molecule Type, Cervical Cancer
Table 16: Number of Products by Stage and Target, Vaginal Cancer
Table 17: Number of Products by Stage and Mechanism of Action, Vaginal Cancer
Table 18: Number of Products by Stage and Route of Administration, Vaginal Cancer
Table 19: Number of Products by Stage and Molecule Type, Vaginal Cancer
Table 20: Number of Products by Stage and Target, Vulvar Cancer
Table 21: Number of Products by Stage and Mechanism of Action, Vulvar Cancer
Table 22: Number of Products by Stage and Route of Administration, Vulvar Cancer
Table 23: Number of Products by Stage and Molecule Type, Vulvar Cancer
Table 24: Cervical Cancer - Pipeline by Abion Inc
Table 25: Cervical Cancer - Pipeline by Abivax SA
Table 26: Cervical Cancer - Pipeline by Admedus Ltd
Table 27: Cervical Cancer - Pipeline by Advaxis Inc
Table 28: Cervical Cancer - Pipeline by Advenchen Laboratories LLC
Table 29: Cervical Cancer - Pipeline by Agenus Inc
Table 30: Cervical Cancer - Pipeline by Amgen Inc
Table 31: Cervical Cancer - Pipeline by AntiCancer Inc
Table 32: Cervical Cancer - Pipeline by Antigen Express Inc
Table 33: Cervical Cancer - Pipeline by Arbor Vita Corp
Table 34: Cervical Cancer - Pipeline by ArQule Inc
Table 35: Cervical Cancer - Pipeline by Asana BioSciences LLC
Table 36: Cervical Cancer - Pipeline by AstraZeneca Plc
Table 37: Cervical Cancer - Pipeline by AVEO Pharmaceuticals Inc
Table 38: Cervical Cancer - Pipeline by Bayer AG
Table 39: Cervical Cancer - Pipeline by BeiGene Ltd
Table 40: Cervical Cancer - Pipeline by Bioleaders Corp
Table 41: Cervical Cancer - Pipeline by Biomics Biotechnologies Co Ltd
Table 42: Cervical Cancer - Pipeline by Blirt SA
Table 43: Cervical Cancer - Pipeline by Boehringer Ingelheim GmbH
Table 44: Cervical Cancer - Pipeline by Bristol-Myers Squibb Co
Table 45: Cervical Cancer - Pipeline by Cadila Healthcare Ltd
Table 46: Cervical Cancer - Pipeline by Cancer Research Technology Ltd
Table 47: Cervical Cancer - Pipeline by Celleron Therapeutics Ltd
Table 48: Cervical Cancer - Pipeline by Coherus BioSciences Inc
Table 49: Cervical Cancer - Pipeline by Critical Outcome Technologies Inc
Table 50: Cervical Cancer - Pipeline by Cytori Therapeutics Inc
Table 51: Cervical Cancer - Pipeline by CZ BioMed Corp
Table 52: Cervical Cancer - Pipeline by DelMar Pharmaceuticals Inc
Table 53: Cervical Cancer - Pipeline by Dr. Reddy's Laboratories Ltd
Table 54: Cervical Cancer - Pipeline by Eisai Co Ltd
Table 55: Cervical Cancer - Pipeline by Etubics Corp
Table 56: Cervical Cancer - Pipeline by Eureka Therapeutics Inc
Table 57: Cervical Cancer - Pipeline by EyeGene Inc
Table 58: Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd
Table 59: Cervical Cancer - Pipeline by Formune SL
Table 60: Cervical Cancer - Pipeline by GamaMabs Pharma SA
Table 61: Cervical Cancer - Pipeline by Gene Techno Science Co Ltd
Table 62: Cervical Cancer - Pipeline by Genentech Inc
Table 63: Cervical Cancer - Pipeline by Genmab A/S
Table 64: Cervical Cancer - Pipeline by Genor BioPharma Co Ltd
Table 65: Cervical Cancer - Pipeline by GlaxoSmithKline Plc
Table 66: Cervical Cancer - Pipeline by Glycostem Therapeutics BV
Table 67: Cervical Cancer - Pipeline by Glycotope GmbH
Table 68: Cervical Cancer - Pipeline by Gradalis Inc
Table 69: Cervical Cancer - Pipeline by Immunomedics Inc
Table 70: Cervical Cancer - Pipeline by Immunovaccine Inc
Table 71: Cervical Cancer - Pipeline by Innate Pharma SA
Table 72: Cervical Cancer - Pipeline by Innovation Pharmaceuticals Inc
Table 73: Cervical Cancer - Pipeline by Iovance Biotherapeutics Inc
Table 74: Cervical Cancer - Pipeline by ISA Pharmaceuticals BV

List of Figures
Figure 1: Number of Products under Development for Cervical Cancer
Figure 2: Number of Products under Development by Companies, Cervical Cancer
Figure 3: Number of Products under Development by Universities/Institutes, Cervical Cancer
Figure 4: Number of Products under Development for Vaginal Cancer
Figure 5: Number of Products under Development by Companies, Vaginal Cancer
Figure 6: Number of Products under Development for Vulvar Cancer
Figure 7: Number of Products under Development by Companies, Vulvar Cancer
Figure 8: Number of Products by Top 10 Targets, Cervical Cancer
Figure 9: Number of Products by Stage and Top 10 Targets, Cervical Cancer
Figure 10: Number of Products by Top 10 Mechanism of Actions, Cervical Cancer
Figure 11: Number of Products by Stage and Top 10 Mechanism of Actions, Cervical Cancer
Figure 12: Number of Products by Routes of Administration, Cervical Cancer
Figure 13: Number of Products by Stage and Routes of Administration, Cervical Cancer
Figure 14: Number of Products by Top 10 Molecule Types, Cervical Cancer
Figure 15: Number of Products by Stage and Top 10 Molecule Types, Cervical Cancer
Figure 16: Number of Products by Targets, Vaginal Cancer
Figure 17: Number of Products by Stage and Targets, Vaginal Cancer
Figure 18: Number of Products by Mechanism of Actions, Vaginal Cancer
Figure 19: Number of Products by Stage and Mechanism of Actions, Vaginal Cancer
Figure 20: Number of Products by Routes of Administration, Vaginal Cancer
Figure 21: Number of Products by Stage and Routes of Administration, Vaginal Cancer
Figure 22: Number of Products by Molecule Types, Vaginal Cancer
Figure 23: Number of Products by Stage and Molecule Types, Vaginal Cancer
Figure 24: Number of Products by Targets, Vulvar Cancer
Figure 25: Number of Products by Stage and Targets, Vulvar Cancer
Figure 26: Number of Products by Mechanism of Actions, Vulvar Cancer
Figure 27: Number of Products by Stage and Mechanism of Actions, Vulvar Cancer
Figure 28: Number of Products by Routes of Administration, Vulvar Cancer
Figure 29: Number of Products by Stage and Routes of Administration, Vulvar Cancer
Figure 30: Number of Products by Molecule Types, Vulvar Cancer
Figure 31: Number of Products by Stage and Molecule Types, Vulvar Cancer

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abion Inc
  • Abivax SA
  • Admedus Ltd
  • Advaxis Inc
  • Advenchen Laboratories LLC
  • Agenus Inc
  • Amgen Inc
  • AntiCancer Inc
  • Antigen Express Inc
  • Arbor Vita Corp
  • ArQule Inc
  • Asana BioSciences LLC
  • AstraZeneca Plc
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • BeiGene Ltd
  • Bioleaders Corp
  • Biomics Biotechnologies Co Ltd
  • Blirt SA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Cadila Healthcare Ltd
  • Cancer Research Technology Ltd
  • Celleron Therapeutics Ltd
  • Cervical Cancer
  • Coherus BioSciences Inc
  • Critical Outcome Technologies Inc
  • Cutanea Life Sciences Inc
  • Cytori Therapeutics Inc
  • CZ BioMed Corp
  • DelMar Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Ltd
  • Eisai Co Ltd
  • Etubics Corp
  • Eureka Therapeutics Inc
  • EyeGene Inc
  • F. Hoffmann-La Roche Ltd
  • Formune SL
  • GamaMabs Pharma SA
  • Gene Techno Science Co Ltd
  • Genentech Inc
  • Genmab A/S
  • Genor BioPharma Co Ltd
  • GlaxoSmithKline Plc
  • Glycostem Therapeutics BV
  • Glycotope GmbH
  • Gradalis Inc
  • Immunomedics Inc
  • Immunovaccine Inc
  • Innate Pharma SA
  • Innovation Pharmaceuticals Inc
  • Iovance Biotherapeutics Inc
  • ISA Pharmaceuticals BV
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Kaketsuken
  • Karyopharm Therapeutics Inc
  • Kite Pharma Inc
  • LondonPharma Ltd
  • Mabion SA
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Mycenax Biotech Inc
  • Nektar Therapeutics
  • NeoImmuneTech Inc
  • Ology Bioservices Inc
  • Oncobiologics Inc
  • Ono Pharmaceutical Co Ltd
  • Oryx GmbH & Co KG
  • PDS Biotechnology Corp
  • Pfizer Inc
  • Pharma Mar SA
  • Psicofarma SA de CV
  • Puma Biotechnology Inc
  • Regeneron Pharmaceuticals Inc
  • Rexahn Pharmaceuticals Inc
  • Richter Gedeon Nyrt
  • Samyang Holdings Corp
  • Sanofi
  • Seattle Genetics Inc
  • Selecta Biosciences Inc
  • Shantha Biotechnics Pvt Ltd
  • Sirnaomics Inc
  • Sun Pharma Advanced Research Company Ltd
  • Taiwan Liposome Company Ltd
  • Tessa Therapeutics Pte Ltd
  • Theralase Technologies Inc
  • Theravectys SA
  • THEVAX Genetics Vaccine USA Inc
  • UbiVac LLC
  • Vectorite Biomedica Inc
  • VLPbio
  • Wellstat Biologics Corp
  • Zeria Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll